Aptamer discovery and technology have made significant strides in recent years, driven by their ability to target a wide range of molecules with high specificity and affinity. The systematic approach to discovering aptamers, combined with advancements in technology, has broadened their application in fields like therapeutics, diagnostics, and biosensing. Here’s a comprehensive analysis of aptamer discovery …
Introduction Aptamers are single-stranded oligonucleotides that fold into unique 3D structures to bind targets with high specificity. Often called “chemical antibodies,” they offer advantages over traditional protein binders. These molecules are discovered through SELEX (Systematic Evolution of Ligands by Exponential Enrichment), an iterative in vitro process that isolates high-affinity ligands from massive random libraries. The …
SELEX Technology: Expert Guide to Choosing Between RNA and DNA Aptamers Overview of SELEX Technology Systematic Evolution of Ligands by EXponential enrichment (SELEX) is the gold-standard in vitro process for screening nucleic acid aptamers. This technology operates by cycling through “incubation-separation-amplification” steps to isolate high-affinity sequences from massive libraries (10¹³–10¹⁵ variants). While SELEX offers superior …
Bridging the Gap in TKI-Resistant NSCLC: The Strategic Rise of Antibody-Drug Conjugates (ADCs) Introduction The treatment landscape for Non-Small Cell Lung Cancer (NSCLC) has been revolutionized by EGFR Tyrosine Kinase Inhibitors (TKIs). However, the inevitable development of acquired resistance limits their long-term efficacy. To bridge this therapeutic gap, Antibody-Drug Conjugates (ADCs) have emerged as a …